LEO Pharma Announces Publication of Adbry™ (tralokinumab-ldrm) Efficacy Data in Moderate-to-Severe Atopic Dermatitis in American Journal of Clinical Dermatology
Post-hoc analysis from ECZTRA 3 showed improvements in extent and severity of atopic dermatitis, sleep interference, and quality of life in adult patients treated with Adbry plus topical corticosteroids as needed over 32 weeks.1 MADISON, N.J.–(BUSINESS WIRE)–LEO Pharma A/S, a global leader in medical dermatology, today announced that American Journal of Clinical Dermatology published 32-week … [Read more…]
